Daclizumab versus anti-thymocyte globulin-fresenius as induction therapy for low-risk kidney transplant recipients.

MM Abou-Jaoude, I Ghantous, R Najm, C Afif, WY Almawi

Research output: Chapter in Book/Report/Conference proceedingConference contribution

7 Citations (Scopus)
Original languageEnglish
Title of host publicationTransplantation proceedings
Pages2731
Number of pages1
Volume35
Publication statusPublished - 2003

Cite this